DURINERT Trademark

Trademark Overview

On Friday, September 20, 2019, a trademark application was filed for DURINERT with the United States Patent and Trademark Office. The USPTO has given the DURINERT trademark a serial number of 88624711. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 24, 2023. This trademark is owned by CSL Behring GmbH. The DURINERT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of blood or bleeding disorders; blood products for the treatment of hereditary angioedema; blood proteins for therapeutic use
durinert

General Information

Serial Number88624711
Word MarkDURINERT
Filing DateFriday, September 20, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 24, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 28, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of blood or bleeding disorders; blood products for the treatment of hereditary angioedema; blood proteins for therapeutic use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 26, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCSL Behring GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMarburg 35041
DE
Party NameCSL Behring GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMarburg 35041
DE

Trademark Events

Event DateEvent Description
Monday, April 24, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 24, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, September 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 7, 2022SOU EXTENSION 5 GRANTED
Wednesday, August 24, 2022SOU EXTENSION 5 FILED
Wednesday, September 7, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 24, 2022TEAS EXTENSION RECEIVED
Saturday, February 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 24, 2022SOU EXTENSION 4 GRANTED
Thursday, February 24, 2022SOU EXTENSION 4 FILED
Thursday, February 24, 2022TEAS EXTENSION RECEIVED
Thursday, August 26, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 24, 2021SOU EXTENSION 3 GRANTED
Tuesday, August 24, 2021SOU EXTENSION 3 FILED
Tuesday, August 24, 2021TEAS EXTENSION RECEIVED
Friday, February 26, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 24, 2021SOU EXTENSION 2 GRANTED
Wednesday, February 24, 2021SOU EXTENSION 2 FILED
Wednesday, February 24, 2021TEAS EXTENSION RECEIVED
Saturday, August 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 20, 2020SOU EXTENSION 1 GRANTED
Thursday, August 20, 2020SOU EXTENSION 1 FILED
Thursday, August 20, 2020TEAS EXTENSION RECEIVED
Tuesday, March 24, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 28, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 28, 2020PUBLISHED FOR OPPOSITION
Wednesday, January 8, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, December 23, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 20, 2019ASSIGNED TO EXAMINER
Thursday, September 26, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 24, 2019NEW APPLICATION ENTERED

Related Keywords

durinert blood treatment angioedema proteins therapeutic hereditary disorders preparations bleeding pharmaceutical